CollPlant Biotechnologies Ltd. filed a Form 6-K on November 2, 2026, disclosing that its Board of Directors replaced Yehiel Tal as Chief Executive Officer with Eran Rotem, effective immediately, as part of a broader cost-reduction plan that includes discontinuing regenerative medicine research and development activities.

Key Highlights

  • CEO change, effective immediately: The Board determined that Yehiel Tal would cease serving as Chief Executive Officer on November 2, 2026.
  • Rotem appointed CEO: Eran Rotem, previously Deputy Chief Executive Officer and Chief Financial Officer, was named Chief Executive Officer while retaining the CFO role.
  • Compensation unchanged: According to the filing, Mr. Rotem's compensation terms will remain unchanged at this time.
  • Tal remains a Board member: Mr. Tal resigned as Interim Chairman of the Board but will continue to serve as a director.
  • Regenerative medicine R&D discontinued: As part of the cost-reduction plan, the company is discontinuing its regenerative medicine research and development activities.
  • rhCollagen production continues: The filing states the plan does not affect production of recombinant human collagen (rhCollagen) at facilities in Yessod Hama'ala and Rehovot, Israel.

CollPlant's Leadership Shift and Cost-Reduction Plan Details

According to the Form 6-K filed with the U.S. Securities and Exchange Commission, the Board of Directors of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) determined on November 2, 2026, that Yehiel Tal would cease serving as Chief Executive Officer effective immediately. The filing states this determination "was made in connection with a broader cost-reduction plan designed to optimize the Company's operating expenses."

The Board simultaneously appointed Eran Rotem, who had served as the company's Deputy Chief Executive Officer and Chief Financial Officer, to the role of Chief Executive Officer. The filing discloses that Mr. Rotem will continue to hold the CFO title alongside the new CEO designation, and that his compensation terms will remain unchanged at this time. Mr. Tal, separately, resigned as Interim Chairman of the Board on the same date, though he will remain a Board member. The filing notes that the terms of Mr. Tal's separation, including any amounts payable to him, "will be in accordance with his employment agreement, the Company's Compensation Policy for Executive Officers and Directors and applicable law."

As part of the same cost-reduction plan, the company disclosed it is discontinuing its regenerative medicine research and development activities. However, the filing specifies that this plan does not affect rhCollagen production, which is carried out at the company's facilities in Yessod Hama'ala and Rehovot, Israel. The company stated it "plans to continue to produce and supply rhCollagen and rhCollagen-based bioinks to its business partners, collaborators and customers."

What Was Disclosed

CollPlant Biotechnologies Ltd. disclosed a CEO transition from Yehiel Tal to Eran Rotem effective November 2, 2026, tied to a cost-reduction plan that discontinues regenerative medicine R&D while preserving rhCollagen production operations.